🏛️ Verified NIH Record • Updated 2026-06-18

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation (NCT05609578)

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Mirati Therapeutics Inc.

🩺 Plain-English Summary (8th-Grade Level)

Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation

Who can join: Review the eligibility criteria below.

Location: Local Institution - 017-936C — Fountain Valley, California

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (94 Sites)

  • Local Institution - 017-936C — Fountain Valley, California
  • Local Institution - 017-936 — Fountain Valley, California
  • Local Institution - 017-851 — Fullerton, California
  • Local Institution - 017-540 — San Francisco, California
  • Local Institution - 017-872-I — Aurora, Colorado
  • Local Institution - 017-872-G — Boulder, Colorado
  • Local Institution - 017-872-D — Colorado Springs, Colorado
  • Local Institution - 017-872-J — Colorado Springs, Colorado
  • Local Institution - 017-872-B — Denver, Colorado
  • Local Institution - 017-872-F — Denver, Colorado
  • Local Institution - 017-872-A — Lakewood, Colorado
  • Local Institution - 017-872-C — Littleton, Colorado
  • Local Institution - 017-872 — Lone Tree, Colorado
  • Local Institution - 017-872-E — Pueblo, Colorado
  • Local Institution - 017-872-H — Thornton, Colorado
  • Local Institution - 017-829 — Jacksonville, Florida
  • Local Institution - 017-898 — Lakeland, Florida
  • Local Institution - 017-972 — Chicago, Illinois
  • Local Institution - 017-820J — Fairway, Kansas
  • Local Institution - 017-820A — Kansas City, Kansas
  • Local Institution - 017-820B — Kansas City, Kansas
  • Local Institution - 017-820C — Kansas City, Kansas
  • Local Institution - 017-820H — Kansas City, Kansas
  • Local Institution - 017-820I — Overland Park, Kansas
  • Local Institution - 017-820 — Westwood, Kansas

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗